Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience

Br J Haematol. 2022 Sep;198(6):1073-1075. doi: 10.1111/bjh.18339. Epub 2022 Jun 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD19
  • Biological Products
  • Feasibility Studies
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse*
  • Outpatients
  • Receptors, Chimeric Antigen
  • Telemedicine*

Substances

  • Antigens, CD19
  • Biological Products
  • Receptors, Chimeric Antigen
  • brexucabtagene autoleucel
  • axicabtagene ciloleucel